Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Decitabine and Venetoclax in Combination with Olutasidenib for the Treatment of Patients with Newly Diagnosed, Recurrent or Refractory Acute Myeloid Leukemia

Trial Status: active

This phase Ib/II trial tests the safety, side effects, and best dose of decitabine and venetoclax in combination with olutasidenib in treating patients with acute myeloid leukemia that is newly diagnosed, has come back after a period of improvement (recurrent) or has not responded to previous treatment (refractory). Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Olutasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving decitabine and venetoclax in combination with olutasidenib may be safe, tolerable and effective in treating patients with newly diagnosed, recurrent or refractory AML.